{"nctId":"NCT00515177","briefTitle":"Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study","startDateStruct":{"date":"2007-08"},"conditions":["Chronic Insomnia","Primary Insomnia"],"count":30,"armGroups":[{"label":"MBSR","type":"EXPERIMENTAL","interventionNames":["Behavioral: Mindfulness-Based Stress Reduction"]},{"label":"PCT Sleeping Pills","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: eszopiclone"]}],"interventions":[{"name":"Mindfulness-Based Stress Reduction","otherNames":[]},{"name":"eszopiclone","otherNames":["LUNESTAÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic insomnia defined as a) sleep onset latency and/or wake after sleep onset longer than 30 minutes per night, at least 3 nights per week; and b) Insomnia duration of at least 6 months, by self-report; and c) minimum of 1 daytime complaint by self-report (e.g. fatigue, mood disturbance);\n* Between 18 and 65 years of age;\n* English-speaking;\n* Literate;\n* Mentally intact;\n* Interested in either medication or mind-body interventions;\n* Able to attend weekly classes in a Minnesota Metro area;\n* Able to comply with study sleep monitoring requirements;\n* Willing to complete the informed consent process.\n\nExclusion Criteria:\n\n* Sleep apnea or other primary sleep disorder suspected of being responsible for insomnia;\n* Mental disorder or substance (including medications) suspected of being responsible for insomnia;\n* General medical condition suspected of being responsible for the insomnia;\n* Medically unstable (a hospital admission for non-elective purposes in the last 3 months or major surgery planned in the next 3 months);\n* Serious preexisting mental health issues: suicidality or thought disorder/psychosis; or delirium or substance abuse;\n* Treatment for depression or anxiety with initiation of therapy or dosage change within the last 6 months;\n* Use of non-prescription sleep aids and unwilling or unable to discontinue these during the study;\n* Use of prescription sleep medications or other medications known to affect sleep or be contraindicated with use of hypnotics, and unwilling or unable to discontinue these during the study;\n* Known allergy to eszopiclone;\n* Shift worker;\n* Pregnant , breast-feeding or planning pregnancy in next 6 months;\n* Previous cognitive behavioral therapy for insomnia or current psychotherapy;\n* Prior MBSR class or regularly practicing mindfulness meditation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pittsburgh Sleep Quality Index (PSQI)","description":"The PSQI is a 19-item self-reported sleep quality measure with scores that range from 0 to 21, where higher scores indicate worse sleep quality. Scores greater than 5 indicate poor sleep.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"3.6"},{"groupId":"OG001","value":"9.2","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"4.6"},{"groupId":"OG001","value":"8.2","spread":"2.7"}]}]}]},{"type":"PRIMARY","title":"Insomnia Severity Index","description":"The Insomnia Severity Index is a 7-item scale that provides a total score indicating current (e.g., last 2 weeks) severity of insomnia symptoms with scores that can range from 0 to 28. Scores of 15 or higher indicate clinical insomnia.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"4.2"},{"groupId":"OG001","value":"9.1","spread":"4.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"5.5"},{"groupId":"OG001","value":"7.8","spread":"4.3"}]}]}]},{"type":"PRIMARY","title":"Actigraphy","description":"Total Sleep Time from Actigraphy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"0.8"},{"groupId":"OG001","value":"6.9","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"State-Trait Anxiety Inventory (STAI)","description":"The STAI is a 20 item scale that measures current anxiety symptoms with scores that range from 20 to 80, with higher scores indicating greater levels of anxiety. The norm for working adults is a score of 34.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":"12.0"},{"groupId":"OG001","value":"31.3","spread":"14.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":"11.8"},{"groupId":"OG001","value":"28.3","spread":"8.5"}]}]}]},{"type":"SECONDARY","title":"Center for Epidemiological Studies Depression Scale (CES-D)","description":"The CES-D is a 20-item self-report scale to measure symptoms of depression in the past week with scores having a range of 0 to 60 and a score of 16 or higher indicating clinically relevant symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"8.5"},{"groupId":"OG001","value":"10.1","spread":"12.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"7.6"},{"groupId":"OG001","value":"7.0","spread":"5.8"}]}]}]},{"type":"SECONDARY","title":"Medical Outcome Study Short Form (SF-12)","description":"Mental component summary score (MCS) of the SF-12 is a self-reported measure of mental health-related quality of life. Scores are reported as standardized T-scores, where an average (mean) score in the general population is 50 with a standard deviation of 10. Scores of 40 or less indicate impaired mental health quality or function.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":"8.5"},{"groupId":"OG001","value":"48.3","spread":"12.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":"10.1"},{"groupId":"OG001","value":"50.1","spread":"6.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":["Taste disturbance","Excessive sleepiness","Headache","Dizziness","Reflux"]}}}